亚宝药业集团股份有限公司关于签订中药新药项目技术转让协议的公告

Transaction Overview - The company signed a technology transfer agreement with Shanxi Traditional Chinese Medicine Research Institute for the new Chinese medicine project "Chaiqin Ning Shen Granules" for a total of RMB 22 million [2][16] - The agreement includes the clinical trial approval, patent rights, and related technical materials for the drug [2][4] Counterparty Information - Shanxi Traditional Chinese Medicine Research Institute, established in 1957, is a leading institution in TCM research and has received numerous accolades and approvals for its contributions to the field [3] - The institute has undertaken over 1,033 research projects and has been recognized with multiple provincial and national awards [3] Product Details - The product "Chaiqin Ning Shen Granules" is classified as a Category 1.1 new drug and is designed to treat insomnia and anxiety symptoms [4][5] - The drug received clinical trial approval from the National Medical Products Administration in January 2025 [5] Agreement Details - The agreement stipulates that the company will pay the total amount of RMB 22 million based on milestone achievements related to the drug's development [6][11] - The payment structure includes specific amounts tied to the completion of various stages of clinical trials and regulatory approvals [12] Impact on the Company - The acquisition of the new drug's clinical trial approval and patent rights is expected to enhance the company's R&D pipeline and improve its competitive edge in the market [16] - The company aims to expedite the development of new products, aligning with its strategic goals and benefiting shareholders [16]